Ascendis Pharma A/S (NASDAQ:ASND) is set to release its earnings data after the market closes on Thursday, November 16th. Analysts expect Ascendis Pharma A/S to post earnings of ($0.81) per share for the quarter.
Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Friday, August 18th. The biotechnology company reported ($1.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.24). Ascendis Pharma A/S had a negative net margin of 2,977.70% and a negative return on equity of 67.76%. The company had revenue of $0.44 million during the quarter, compared to analyst estimates of $0.78 million. During the same quarter last year, the business earned ($0.53) EPS. The company’s revenue for the quarter was down 61.4% compared to the same quarter last year. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of Ascendis Pharma A/S (NASDAQ ASND) opened at $35.50 on Wednesday. Ascendis Pharma A/S has a 1 year low of $18.74 and a 1 year high of $42.00.
A number of equities research analysts have commented on the company. Wells Fargo & Company restated a “buy” rating and set a $51.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Wedbush restated an “outperform” rating and set a $10.71 price objective (down from $65.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Credit Suisse Group AG set a $28.00 price objective on Ascendis Pharma A/S and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Zacks Investment Research lowered Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Wednesday, August 23rd. Finally, Leerink Swann restated a “hold” rating and set a $28.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, September 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Ascendis Pharma A/S presently has a consensus rating of “Hold” and an average target price of $36.95.
WARNING: “Ascendis Pharma A/S (ASND) Scheduled to Post Earnings on Thursday” was originally posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://weekherald.com/2017/11/15/ascendis-pharma-as-asnd-scheduled-to-post-earnings-on-thursday.html.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.